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ISSNObjective: To determine initial 24-week outcomes among prospectively enrolled
patients with failure of initial antiretroviral therapy (ART).
Methods: Baseline virologic failure was defined as HIV-1 viral load greater than 1000
copies/ml. Second-line ART was informed by results of genotype testing and selected
from agents in the South-African public sector. Twenty-four week endpoints included
virologic suppression and mortality.
Results: The cohort consisted of 141 patients (median CD4 cell count and viral load at
failure of 173 cells/ml and 17500 copies/ml). The median prior duration of initial ART
was 12.0 months. At least one major resistance mutation was found in 87% of patients.
After 24 weeks of follow-up, intent-to-treat virologic suppression (<50copies/ml) was
65%, as-treated virologic suppressionwas78%, themedianCD4cell count improvement
was 88 cells/ml and the mortality was 6%. The median CD4 cell count at initial virologic
failure among those who died was 70 cells/ml, compared to 182 cells/ml among patients
who survived (P¼0.01). Patientswithwild-typevirus at initial failure (N¼19)had inferior
outcomes after switch. The presence of nucleoside analogue resistance mutations at
failure did not affect early efficacy of boosted-protease inhibitor regimens.
Conclusions: Virologic monitoring linked to resistance testing helped demonstrate the
efficacy of lopinavir/ritonavir-containing second-line regimens in South Africa. A
switch to second-line regimens in patients with virologic failure and drug resistance
has substantial and rapid immunological and clinical benefits. Resistance testing
identified a high-risk group without resistance who might benefit from increased
medication access and/or adherence support.
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As the number of patients receiving first-line antire-
troviral therapy (ART) has expanded in South Africa, so
too have the number experiencing first-line ART
regimen failure [1–4]. Previously, we reported that
specific resistance mutations encountered in South Africa
at first ART failure include M184V/I (64%), K103N
(51%), thymidine analog resistance mutations (TAMs;
32%), V106M (19%) and protease inhibitor resistance
mutations (4%) [5]. However, there are limited data
describing the treatment response after first-line ART
failure in resource-limited settings. We report the clinical
and virologic outcomes of patients who experienced
initial ART regimen failure in KwaZulu Natal, South
Africa, after 24 weeks of second-line ART.Methods
The Sinikithemba Clinic at McCord Hospital and the
iThemba Clinic at St. Mary’s Hospital in South Africa
provide vertical HIV care for patients from KwaZulu-
Natal. Monitoring follows South African Department of
Health recommendations including HIV-1 viral load
(detection limit of <50 copies/ml) and CD4 cell count
monitoring 6-monthly. Clinic counselors provide Adher-
ence training is provided before ART initiation and after
any elevated viral load.
Study participants
Patients (n¼ 115)were prospectively enrolled adultswith a
single episode of virologic failure (HIV-1 RNA viral load
1000 copies/ml) during initial combination ARTwho
underwent genotypic resistance testing. Patients with a
prior historyof dual or monotherapywere not excluded. A
subset of patients (n¼ 26; 18% of overall cohort) had
resistance testing performed prior to the inception of the
prospective cohort in 2005 and were added to the overall
cohort. The second-line agents available during the study
were lopinavir/ritonavir [LPV/r; available as gel formu-
lation (Kaletra)]; lamivudine, didanosine (enteric-coated
formulation); zidovudine; stavudine; nevirapine and
efavirenz. The option to continue a non-nucleotide
reverse transcriptase inhibitor (NNRTI)-based regimen
after initial ART failure was available.
Data collection
Data collected at regimen failure included treatment
history, CD4 cell count, HIV-1 RNA level, WHO stage,
hemoglobin and weight. Data collected after 24 weeks of
subsequent ART included plasma HIV-1 RNA, CD4 cell
count and clinical outcome.
Genotypic resistance testing
Genotypic testing of virus samples was performed at the
Nelson Mandela School of Medicine (Durban), using the
TRUGENE HIV-1 Genotyping Test (Siemens). Majorpyright © Lippincott Williams & Wilkins. Unauthorresistance mutations were previously defined in the initial
report describing the cohort [5].
Statistical analysis
Analyses were performed using SAS software, version
9.1.3 (SAS Institute, Cary, North Carolina, USA). All
tests of significance were two-sided; associations with
P< 0.05 were considered significant. Continuous vari-
ables were compared with Wilcoxon rank-sum test;
categorical variables with the x2 test or Fisher’s exact test.
An intent-to-treat (ITT) (missing¼ failure) analysis was
performed for the primary outcome of virologic
suppression (<50 copies/ml) 24 weeks from enrollment.
All outcomes among patients with and without major
drug resistance mutations were compared using the x2 test
and Fisher’s exact test. A multivariate logistic regression
was performed to determine risk factors associated with
mortality after regimen failure.
The study was approved by the ethics committees at
McCord and St. Mary’s Hospital and by the IRB at
Partners HealthCare and Harvard Medical School in
Boston, Massachusetts.Results
Patient characteristics
Between August 2004 and August 2006, 141 patients
experienced initial ART virologic failure and underwent
genotypic testing. Table 1 shows patient characteristics at
regimen failure. At least one major resistance mutation at
regimen failure was found for 122 (87%) patients and 19
(13%) patients had no major resistance mutation detected
(‘wild-type’ genotype).
Virologic and immunological outcomes at 24
weeks
Intent-to-treat analysis showed that 24 weeks after
virologic failure, 99 (70%) patients achieved viral
suppression to less than 400 copies/ml, and 91 (65%)
patients to less than 50 copies/ml. Overall, 50% of patients
achieved a 30% improvement in CD4 cell count at
24 weeks follow-up; the median 24-week increase in
CD4 cell count was 88 cells/ml [interquartile range (IQR)
7–168]. After 24 weeks, the median 24-week CD4 cell
count was 249 cells/ml (166–343) and only 33% of
patients remained with a CD4 cell count of less than
200 cells/ml.
Mortality and loss-to-follow-up at 24 weeks
The overall mortality among patients 24 weeks after
initial ART virologic failure was 6% [95% confidence
interval (CI) 2–9%], and loss-to-follow-up was 9% (95%
CI 4–13%). Causes of death were tuberculosis (three
patients), gastroenteritis (two), lactic acidosis (one),
suspected central nervous system mass (one), andized reproduction of this article is prohibited.
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Table 1. Baseline characteristics of patients with virologic failure during first-line ART with and without evidence of genotypic drug resistance.
Characteristic
1 Major resistance
mutation (N¼122)
No major mutation
detected (N¼19)
Median age (years) (IQR) 36 (30–42) 43 (35–47)M
Women (%) 51 47
WHO classification (%)
Class 1 20 21
Class 2 23 21
Class 3 37 42
Class 4 20 16
ART regimen at virologic failure (%)
D4T – 3TC – EFV 40 63
D4T – 3TC – NVP 7 0
ZDV – 3TC – EFV 29 16
ZDV – 3TC – NVP 12 10
D4T – DDI – EFV 2 0
Other 10 11
Prior dual or monotherapy (%) 20 21
Median months of NNRTI-based ART (IQR) 13 (7–20) 8 (6–12)M
Median CD4 cell count at virologic failure (cells/ml) (IQR)a 176 (112–259) 128 (103–221)
CD4 cell count category (cells/ml) (%)a
0–49 9 6
50–99 12 17
100–199 36 44
200–349 34 27
350 9 6
Median plasma viral load at virologic failure (copies/ml) (IQR)b 17 000 (5500–68264) 26 766 (2500–250000)
Viral load category (copies/ml) (%)b
400–4999 22 32
5000–29999 38 20
30000–99999 23 11
100000 17 37
Median hemoglobin (g/dl) (IQR)c 13 (11–14) 12 (11–13)
Resistance mutations (%)
TAM1 14 NA
TAM2 30 NA
K65R 6 NA
Dual class resistance (1 major NRTI and NNRTI mutation) 21 NA
ART regimen following virologic failure (%)
Lopinavir/ritonavir-based 90 21MM
Nonprotease-inhibitor-based 7 63
No subsequent regimen 3 16
Wilcoxon, chi-squared, and Fisher’s tests used for two groups. ART, antiretroviral therapy; DDI, didanosine; D4T, stavudine; EFV, efavirenz; IQR,
interquartile range; NNRTI, non-nucleotide reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine;
ZDV, zidovudine; 3TC, lamivudine.
aTwo patients were missing baseline CD4 cell count.
bOne patient was missing baseline viral load.
cEight patients were missing baseline hemoglobin.
MP<0.05.
MMP<0.001.unknown cause (one). Using univariate analysis, we
compared the characteristics of patients who did not
survive 24 weeks of follow-up with those who survived
(Table 2). There was a significant (inverse) relationship
between the CD4 cell count at regimen failure and
24-week mortality, such that patients with CD4 cell
counts at failure of less than 100 cells/ml experienced
higher 24-week mortality compared to patients with
CD4 cell count of at least 100 cells/ml (P¼ 0.005) and
this plausible relationship remained of potential signifi-
cance in the multivariate model. The median CD4 cell
count at initial regimen failure among those who died was
70 cells/ml (IQR 27–123) compared to a CD4 cell count
of 182 cells/ml (114–260) among patients who survivedopyright © Lippincott Williams & Wilkins. Unauth(P¼ 0.01). Patients who received a boosted protease
inhibitor-containing second-line ART after initial regi-
men failure experienced a lower mortality over 24 weeks
(2%) compared to patients who received NNRTI-based
ART (15%) (P¼ 0.004). However, both CD4 cell count
at failure and subsequent regimen type were of border-
line significance in multivariate analysis of mortality
predictors.
Drug resistance at first antiretroviral therapy
failure
Patients in whom one or more HIV-1 drug resistance
mutations were found at virologic failure were com-
pared to patients without resistance mutations detectedorized reproduction of this article is prohibited.
Co
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Table 2. Factors associated with 24-week mortality after initial ART virologic failure.
Characteristics
Univariate
PM
Multivariate
N 24-week mortality no. (%) Odds ratio 95% CI
All patients 141 8 (6)
Sex
Female 71 4 (6)
Male 70 4 (6) 0.98 1.5 (0.2–12.3)
History of suboptimal ART
None 113 7 (6)
Prior dual or monotherapy 28 1 (4) 0.6 0.4 (0.03–7.2)
HIV-1 drug resistance at initial ART failure
1 resistance mutation 122 5 (4)
No resistance 19 3 (16) 0.06 2.1 (0.1–36.2)
Subsequent regimen typea
LPV/r-based ART 114 2 (2)
NNRTI-based ART 20 3 (15) 0.02 6.3 (0.5–83.9)
CD4 cell count at initial ART failure (cells/ml)b
100 110 2 (2)
<100 29 5 (17) 0.005 7.9 (0.8–79.7)
HIV-1 RNA viral load at initial ART failure (copies/ml)c
100000 27 2 (7)
100000 113 6 (5) 0.7 4.1 (0.3–63.7)
WHO clinical stage at initial ART failured
Stage III or stage IV 64 6 (9)
Stage I or stage II 47 2 (4) 0.5 0.4 (0.04–5.8)
ART, antiretroviral therapy; LPV/r, lopinavir/ritonavir; NNRTI, non-nucleotide reverse transcriptase inhibitor.
aSeven patients did not initiate a regimen after virologic failure and three patients from this group died.
bOne patient who died did not have a CD4 cell count at first ART failure.
cOne patient who survived did not have a viral load within 8 weeks of first ART failure.
dThirty patients who survived did not have a recorded WHO staged at first ART failure.
MP values are for univariate logistic regression model; odds ratio refer to the multivariate model logistic regression model.(‘wild-type’ genotype). The two groups did not differ by
age, sex, ART regimen at failure, or by history of prior
dual or monotherapy. The median CD4 cell count at
initial ART failure was 176 cells/ml (IQR 112–259) in
patients with drug resistance and 128 cells/ml (103–222)
in patients without resistance (P¼ 0.34). The median
HIV-1 RNA viral load at failure among patients with
drug resistance was 17 000 copies/ml (IQR 5500–
68 264) and 26 766 copies/ml (2500–250 000) in patients
without resistance (P¼ 0.4). There was no significant
association between the level of viral load at regimen
failure and the presence or absence of drug resistance.
Patients with drug resistance at regimen failurewere more
likely to be started on a ritonavir-boosted protease
inhibitor-containing second-line regimen (90%) com-
pared to patients experiencing virologic failure without
drug resistance (21%) (P¼ 0.001) as clinicians attempted
to optimize regimens.
Viral suppression rates at 24 weeks differed among
patients with and without evidence of drug resistance at
initial virologic failure. At 24 weeks, 84 of 122 patients
(69%) with at least one major mutation achieved viral
suppression compared to 7 of 19 patients (37%) without
resistant virus (ITT analysis; P¼ 0.01). The median 24-
week improvement in CD4 cell count was 89 cells/ml
(IQR 12–168) in patients with baseline drug resistance
and 34 cells/ml (0–160) in patients without resistant viruspyright © Lippincott Williams & Wilkins. Unauthor(P¼ 0.67). After 24 weeks, 4% of patients with drug
resistance and 16% of patients without drug resistance had
died (P¼ 0.02).
Effect of drug resistance on boosted protease
inhibitor-based second-line antiretroviral
therapy outcomes
A total of 107 patients received lopinavir/ritonavir-
containing second-line ART. Among patients who
initiated a lopinavir/ritonavir-containing regimen, viral
suppression at week 24 was achieved in 31 of 39 patients
(79%) with at least one TAM as compared to 69 of 102
patients (68%) with no baseline TAMs (P¼ 0.20) and in 4
of 5 patients who initiated lopinavir/ritonavir with at least
3 TAMS. Early viral suppression on a lopinavir/ritonavir-
containing regimen was achieved in four of five patients
with a K65R mutation. Early viral suppression was also
achieved in four of five patients with evidence of one or
more major protease mutations.Discussion
This is the first prospective study of second-line ART
outcomes in a resource-limited setting. In ITT analysis,
after 24 weeks of subsequent ART, 65% of patients
achieved viral suppression to less than 50 copies/mlized reproduction of this article is prohibited.
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90 cells/ml. The experience of patients in our cohort
compared favorably to that of ART-naive patients in
clinical trials of lopinavir/ritonavir-containing regimens
conducted in high-income settings [6].
The use of genotypic drug resistance testing at first ART
failure provided important insights. The subgroup of
patients in whom no major resistance mutations (‘wild-
type’ genotype) were detected at initial regimen failure
experienced higher mortality and greater subsequent
loss-to-follow-up compared to patients with evidence of
drug resistance. A possible explanation for this para-
doxical observation is the role of poor adherence, which
may not have been resolved before the salvage regimen
was initiated. Risk factors for suboptimal adherence have
been identified in resource-poor contexts including clinic
fees, stigma, regimen complexity, and drug supply
interruptions [3,7–9].
We examined the impact of specific resistance mutations
seen at initial virologic failure on subsequent outcomes.
NRTI resistance mutations (including K65R and
TAMs) had minimal impact on 24-week outcomes
using boosted protease inhibitor-based ART. The high
pharmacological and genetic barriers to resistance to
ritonavir-boosted lopinavir may have allowed patients to
overcome the deleterious effects of major NRTI
resistance mutations. However, these results should
be interpreted with caution given the relatively short
follow-up.
The study has several limitations. Second-line ART
after virologic failure was informed by genotypic
resistance testing and the nucleoside backbone was
optimized based upon resistance mutations at initial
ART failure. Because this study was not conducted as a
controlled clinical trial of the impact of drug resistance
testing, we cannot estimate the direct contribution
of genotype testing on the outcomes. Second, to
maximize the benefit to patients of genotype testing,
with limited exceptions (n¼ 4), lopinavir/ritonavir was
not given to patients with ‘wild-type’ genotypes, a
pattern known to be associated with suboptimal
adherence. If suboptimal adherence to initial ART is
linked to adherence to subsequent regimens, we may
have overestimated the efficacy of lopinavir/ritonavir-
containing second-line ART.
In summary, virologic monitoring linked to resistance
testing helped demonstrate the efficacy of lopinavir/
ritonavir-containing regimens as second-line ART in
South Africa. Resistance testing identified a high-risk
group without drug resistance who might benefit
from increased medication access and/or adherence
support. Although regimens that include LPV/r remain
more expensive than first-line regimens, even at local
access prices, our results suggest that switching toopyright © Lippincott Williams & Wilkins. Unauthsecond-line regimens in patients with virologic failure
and resistance has substantial and rapid immunological
and clinical benefits. Models predict that the prevalence
of HIV drug resistance in sub-Saharan Africa will
grow substantially over the next decade [10]. Early
detection of regimen failure and reductions in the price
of boosted protease inhibitor-based regimens must be
prioritized if this patient population is to be effectively
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